-
Georgy JT, Regi SS, Georgy RV, Sasidharan BK, Joel A, Philip DSJ, John AO, Thumaty DB, Marimuthu PK, Jambunathan P, Harikrishna K, Thomas Z, Rani NJ, Tirkey AJ, Thomas M, Isiah R, Singh A. Low-dose nivolumab plus induction chemotherapy for locally advanced or unresectable head and neck cancer is associated with high response rates and conversion to definitive therapy. Sci Rep. 2025 Oct 8;15(1):35110. doi: 10.1038/s41598-025-19197-y. PMID: 41062634; PMCID: PMC12508025.
-
Marimuthu PK, Georgy JT, Philip DSJ, John AO, Joel A, Thumaty DB, Chacko RT, Jambunathan P, Thomas Z, Harikrishna K, Isiah R, Pavamani SP, Sasidharan B, Mathew M, Alex Kodiatte T, Irodi A, Thangakunam B, Isaac BTJ, Gupta R, Rani J, Singh A. Real-World Outcomes of Induction Chemotherapy With or Without Low-Dose Nivolumab for Stage III Non-Small Cell Lung Cancer Ineligible for Up-Front Local Therapy: A Propensity Score-Matched Analysis. JCO Glob Oncol. 2025 Mar;11:e2400256. doi: 10.1200/GO-24-00256. Epub 2025 Mar 24. PMID: 40127380.
-
Loganathan A, Joseph L, Rabindaranth BR, Rani J, Ebenezer J, Annamalai P, Chacko B. Identifying barriers to incident reporting in a quaternary care hospital. BMJ Open Qual. 2026 Feb 3;15(1):e003245. doi: 10.1136/bmjoq-2024-003245. PMID: 41633769; PMCID: PMC12878494.
